ProPhase Labs, Inc. Share Repurchase Authorization
ProPhase Labs, Inc. (PRPH) had Share Repurchase Authorization of $6.00 million as of 2023-03-15, per its 10-K filed 2025-04-01.
Financial Statements › Notes › Equity
srt:StockRepurchaseProgramAuthorizedAmount1 · last filed 2025-04-01
- 2023-03-15: Stock Repurchase Program Authorized Amount1 $6.00M.
- 2022-07-26: Stock Repurchase Program Authorized Amount1 $6.00M.
| Period end | Stock Repurchase Program Authorized Amount1 |
|---|---|
| 2023-03-15 | $6.00M 10-K · filed 2025-04-01 |
| 2022-07-26 | $6.00M 10-K · filed 2025-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |